Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) is expected to be posting its quarterly earnings results after the market closes on Thursday, March 6th. Analysts expect Oncternal Therapeutics to post earnings of ($2.96) per share and revenue of $0.28 million for the quarter.
Oncternal Therapeutics Stock Performance
Shares of ONCT opened at $0.53 on Thursday. The stock has a 50 day moving average price of $0.53 and a two-hundred day moving average price of $1.44. The firm has a market capitalization of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. Oncternal Therapeutics has a 52 week low of $0.53 and a 52 week high of $13.14.
Wall Street Analysts Forecast Growth
Separately, StockNews.com started coverage on Oncternal Therapeutics in a report on Sunday. They set a “hold” rating for the company. Four equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Further Reading
- Five stocks we like better than Oncternal Therapeutics
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Buffett’s on the Sidelines – Should You Follow?
- What Makes a Stock a Good Dividend Stock?
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
- Which Wall Street Analysts are the Most Accurate?
- 3 Stocks With Triple-Digit PEs That Are Still Worth a Look
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
